Homepage
Author:
Capricor Therapeutics
Posted Date:
May 5, 2026
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics
May 5, 2026
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
Capricor Therapeutics
April 22, 2026
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Capricor Therapeutics
March 13, 2026
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics
March 12, 2026
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Capricor Therapeutics
March 10, 2026
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
Capricor Therapeutics
March 9, 2026
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Capricor Therapeutics
February 24, 2026
